Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria
Status:
Completed
Trial end date:
2015-06-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of 84 days of
daily dosing of 590 mg of LAI versus placebo in patients with treatment refractory NTM lung
disease.
The first part of the study is the 84-day double-blind phase to evaluate the primary and
secondary endpoints.
Phase:
Phase 2
Details
Lead Sponsor:
Insmed Incorporated
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)